| PATENT NUMBER | This data is not available for free |
| PATENT GRANT DATE | January 13, 2004 |
| PATENT TITLE |
Beta-fluoroethyl thiourea compounds and use |
| PATENT ABSTRACT | The present invention relates to compounds, compositions and methods for the prevention or treatment of mycobacterium infections. The compounds are naturally occurring and synthetic biflavonoids, flavonoids, chalcones and chalcone like compounds. The compounds were screened for anti-mycobacterium activity. Of the compounds showing anti-mycobacterium activity, eight were identified as particularly potent, exhibiting greater than 90% inhibition of the growth of Mtb at a concentration of 12.5 .mu.g/mL. The actual minimum inhibitory concentrations (MIC), defined as the lowest concentration inhibiting 99% of the inoculum, for the preferred compounds ranged from 6.8 to 48.3 .mu.M. ##STR1## |
| PATENT INVENTORS | This data is not available for free |
| PATENT ASSIGNEE | This data is not available for free |
| PATENT FILE DATE | September 21, 2000 |
| PATENT REFERENCES CITED |
Aach, R. D. The treatment of chronic type B viral hepatitis. Ann. Intern. Med. 1988, 109, 89-91. Alexander, G. J.; Brahm, J.; Fagan, E. A.; Smith, H. M.; Daniels. H. M.; Eddleston, A. L.; Williams, R., Loss of HBSAg with interferon therapy in chronic hepatitis B virus infection. Lancet 1987, ii, 66-69. Arya, Ranjiana; Babu, Vikas: Ilyas, M.; Nasim, K.T. Phytochemical examination of the leaves of Anaeardium occidentale. J. Indian Chem. Soc., 1989, 66, 67-68. Anand, K.K.; Gupta, V.N.; Rangari, V.; Singh, B.; Chandan, B.K. Structure and hepatoprotective activity of a biflavonoid from Ganarium manii. Planta Medica, 1992, 58, 493-495. Bardos, T.J.; Schinazi, R.F. Ling, K.-H.; Heider, A.R. Structure-activity relationships and mode of action of 5-mercapto-substituted oligo- and polynucleotides as antitemplates inhibiting replication of human immunodeficiency virus type 1. Antimicrob. Agents Chemother., 1992, 36, 108-114. Barre, Sinoussi, F.; Chermann, J.C.; Rey, R.; Nugeyre, L.M.T.; Chamaret, S.; Gruest, J.; Dauguet, C.; Axler-Blin, C.; Vezinet-Brun, F.; Rouzioux, C.; Rozenbaum, W., and Montagnier, L. Isolation of a T-lymphotopic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science, 1983, 220, 868-871. Barron, D.; Ibrahim, R.K. Synthesis of flavanoid sulfates: 1. stepwise sulfaction of position, 3,7, and 4' using N,N'-dicyclohexycarbodiimide and tetrabutylamminium hydrogen sulfate. Tetrahedron, 1987, 43, 5197-5202. Bryson, Y. J.; Monahan, C.; Pollack, M.; Shields, W. D. A prospective double-blind study of side effects associated with the administration of amantadine for influenza A virus prophylaxis. J. Infect. Dis. 1980, 141, 543-547. Chen, F.C.; Lin, Y.M.; Hung, J.C. A new biflavanone glucoside from Garcinia multiflora. Phytochemistry, 1975C, 14, 818-820. Chen, F.C.; Lin, Y.M.; Liang, C.M. Biflavonyls from drupes of Rhus succedanea. Phytochemistry, 1974A, 12, 276-277. Chen, F.C.; Lin, Y.M. Rhusflavanone, a new biflavanone from the seeds of wax tree. J. Chem. Soc., Perkin Trans., 1976, I, 98-101. Chen, F.C.; Lin, Y.M. Succedaneaflavanone--A new 6,6"-biflavanone from Rhus succedanea. Phytochemistry 1975A, 14, 1644-1647. Chen, F.C.; Y.M.; Hung. J.G. Phenolic compounds from the heartwood of Gracinia multiflora. Phytochemistry, 1957B, 14, 300-303. Cholbi, M.R.; Paya, M.; Alcaraz, M.J. Inhibitory effects of phenolic compounds on CCI.sub.4 induced microsomal lipid peroxidation. Experientia, 1991, 47, 195-199. Chou, T.-C.; Talalay, P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enz. Regul., 1984, 22, 27-35. Couch, R. B.; Jackson, G. G. Antiviral agents in influenza--Summary of influenza workshop VIII. J. Infect. Dis. 1976, 134, 516-527. Degelau, J; Somani, S. K.; Cooper, S. L.; Guay, D. R. P.; Crossley, K. B. Amantadine-resistant influenza A in a nursing facility. Arch. Intern. Med. 1992, 152, 390-392. Ono, K.; Nakane, H.; Jukushima, M.; Chermann, J.K.; Barre-Sinoussi, F. Inhibition of reverse transcriptase activity by a flavonoid compound, 5,6,7-trihydroxyflavone. Biochem. Biophys. Res. Commu., 1989, 160, 982-987. Dolin, R.; Reichman, R. C.; Madore, H. P.; Maynard, R.; Lindon, P. M.; Webber-Jones, J. A controlled trial of amantadine and rimandatine in the prophylaxis of influenza A infections. N. Engl. J. Med. 1982, 307, 580-584. Doong, S. L.; Tsai, C. H.; Schinazi, R. F.; Liota, D. C.; Cheng, Y. C. Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues. Pro. Natl. Acad. Sci. USA 1991, 88, 8495-8499. Gallo, R.C.; Salahuddin, S.Z.; Popovic, M.; Shearer, G.M.; Kaplan, M.; Haynes, B.F.; Palker, T.J.; Redfield, R.; Oleske, J.; Safai, B.; White, G.; Foster, P.; Markham, P.D. Frequent and detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science, 1984, 224, 500-503. Geiger, H.; Seeger, T.; Hahn H.; Zinsmeister, H.D. 1H NMR Assignments in biflavanoid spectra by proton-detected C-H correlation. Z. Naturforsch, 1993, 48c, 821-826. Hayashi, T.; Morita, N. Mechanism of action of the antiherpesvirus biflavone ginkgetin. Antimicrob. Agents Chemother., 1992, 36, 1890-1893. Hayden, F. G.; Belshe, R. B.; Clover, R. D.; Hay A. J.; Oakers, M. G.; Soo, W. Emergence and apparent transmission of rimantadine-resistant influenza virus in families. N. Engl. J. Med. 1989, 321, 1696-1702. Hoffman, C. E. Amantadine HC1 and related compounds. In Selective Inhibitors of Viral Functions; Carte, W. A., Ed.; CRC Press: Cleveland, 1973, 199-211. Hoffnagle, J. H. Chronic hepatitis B, N. Engl. J. Med. 1990, 323, 337-339. Huang, L.; Kashiwade, Y.; Cosentino, L.M.; Fan, S.; Chen, C.H.; McPhail, A.T.; Fujoika, T.; Mihasha, K.; and Lee, K.H. Anti-AIDS Agents. 15. Synthesis and Anti-HIV Activity of Dihydroseselins and Related Analogs. J. Med. Chem., 1994, 37, 3947-3955. Iwu, M.M.; Igbokao, O.A.; Onwuchekwa, U.A; Okunii, C.O. Evaluation of the antihepatotoxic activity of the biflavonoids of Garcinia kola seed. J. Ethnopharmacol., 1987, 21, 127-138. Kimberlin, D. W.; Crampacker, C. S.; Straus, S. E.; Biron, K K.; Drew, W. L.; Hayden, F. G.; McKinlay, M.; Richman, D. D.; Whitley, R. J. Antiviral resistance to clinical practice. Antiviral Res., 1995, 26, 423-438. Knight, V.; Gilbert, B. E. Ribavirin aerosol treatment of influenza. In Infectious Disease Clinics of North America, vol. 1.; Moellering, Jr.. Ed.; 1987, 441-457. Konoshima, T.; Takasaki, M.; Kozuka, M.; Lin, Y.M.; Chen, F.C.; Tokuda, H.; Matsumoto, T. Studies on inhibitors of skin tumors promotion (IV). Inhibitory effects of flavonoids on Epstein-Barr virus activation (1). Shoyakugaku Zasshi, 1988, 42, 343-346. Korba, B.E.; Milman, G. A cell culture assay for compounds which inhibit hepatitis B virus replication. Antiviral Res., 1991, 15, 217-228. Korba, B.E.; Gerin, J.L. Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antiviral Res., 1992, 19, 55-70. Korba, B.E.; Gerin, J.L. Antisense oligonucleotides are effective inhibitors of hepatitis B virus replication in vitro. Antiviral Res., 1995, 28, 225-242. Li-zhen, X.; Chem, Z.; sun, N. Studies of Chemical Compositions of Podocarpus nerifolius D. Don. Zhiwu Xuebao, 1993, 35, 138-143 (English Abstract). Lin, Y.M.; Chen. F.C. Robustaflavone from the seed-kernels of Rhus succedanea. Phytochemistry, 1974, 13, 1617-1619. Lin, Y.M.; Chen, F.C. Agathisflavone from the drupes of Rhus succedanea. Phytochemistry, 1974B, 13, 657-658. Lin, Y,M,; Chen. F.C.; Lee, K.H. Hinokiflavone, a cytotoxic principle from Rhus succdeanea and the cytoxicity of the related biflavonoids. Planta Medica, 1989, 55, 166-168. Lopez-Saez, J.A.; Perez-Alonso, M.; Negueruela, A.V. Biflavanoids of Selaginella denticulata growing in Spain. Z. Naturforsch., 1994, 49c, 267-270. Magri, N.J.; Kinston, D.G.I. Modified Toxols, 4. Synthesis and biological activity of toxols modified in the side chain. J. Nat. Prod., 1987, 51, 298-306. Markham, K.R.; Sheppard, C.; Geiger, H. .sup.13 C NMR studies of some naturally occurring amentoflavone and hinokiflavone biflavanoids. Phytochemistry, 1987, 26, 3335-3337. Martin, P. and Friedman, L. S. In Innovations in Antiviral Development and the Detection of Virus Infections; T. M. Block; D. Junkind; R. L. Crowell; M. Dension; L. R. Walsh, Ed.; Plenum Press: New York, 1992, 111-120. Mast, E. E.; Harmon, M. W.; Gravenstein, S.; Wu, S. P.; Arden, H. H.; Circo, R.; Tyszka, G.; Kenal, A. P.; Davis, J. P. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A(H3N2). Am J. Epidemiol. 1992, 134, 988-997. McDougal, J.S.; Cort, S.P.; Kennedy, M.S.; Cabridilla, C.D.; Feorino, P.M.; Francis, D.P.; Hicks, K.; Kalyanaramen, V.S.; Martin, L.S. Immunoassay for the detection and quantitation of infectious human retrovirus, lymphadenopathy-associated virus (LAV). J. Immun. Meth. 1985, 76, 171-183. Mora, A.; Paya, M.; Roips, K. Structure-activity relationships of polymethoxyflavones and other flavonoids as inhibitor of non-enzymatic lipid peroxidation. Biochem-Pharmacol., 1990, 40, 793-797. Muller, C.; Bergmann, K.F.; Gerin, J.L.; Korba, B.E. Production of hepatitis B virus by stably transfected monocytic cell line U-937: a model for extrahepatic hepatitis B virus replication. J. Infect. Dis., 1992, 165, 929-933. Murakami, A.; Ohigashi, H.; Jisaka, M.; Irie, R.; Koshimizu, K. Inhibitory effects of new types of biflavonoid-related polyphenols; lophirone A and lophiraic acid, on some tumor promoter-induced biological responses in vitro and in vivo. Cancer Lett. (Shannon, Irel.), 1991, 58, 101-106. Nagai, T.; Miyaichi, Y.; Tomimori, T.; Suzuki, Y.; Yamada, N. Inhibition of influenza virus sialidase and anti-influenza virus activity by plant flavonoids. Chem. Pharm. Bull., 1990, 38, 1329-1332. Nagai, T.; Miyaichi, Y.; Tomimore, T.; Suzuki, Y.; Yamada, H. In vivo anti-influenza virus activity of plant flavonoids possessing inhibitory activity for influenza virus sialidase. Antiviral Res., 1990, 19:207-217. Nagai, T.; Suzuki, Y.; Tomimore, T.; Yamada, H. Antiviral activity of plant flavonoid, 5,7,4'-trihydroxy-8-methoxyflavone, from roots of Scutellaria baicalenais against influenza A (H3N2) and B viruses. Biol. Pharm. Bull., 1995, 18, 295-299. Nagai, T.; Moriguchi, R.; Suzuki, Y.; Tomimori, T.; Yamada, H. Mode of action of the anti-influenza virus activity of plant flavonoid, 5,7,4'-trihydroxy-8-methoxyflavone, form the roots of Scutellaria baicalensis. Antiviral Res. 1995, 26, 11-25. Nakazawa, K. Chemical structure of ginkgetin. Gifu Yakka Diagaku. Kiyo, 1941, 12, 1, Chem. Abst. 59, 2759d. Ono, K.; Nakane, H.; Jukushima, M.; Chermann, J.K.; Barre-Sinlussi, F. Differential inhibitory effects of various flavonoids on the activities of reverse transcriptase and cellular DNA and RNA polymerases. Euro. J. Biochem., 1990, 190, 469-476. Qasim, M.A., Roy, S.K.; Ilyas, M. Phenolic Constituents of Selaginellaceae. Indian Journal of Chemistry, 1985, 24B, 220. Ray, C. G.; Icenogle, T. B.; Minnich, L. L; Copeland, J. G.; Grogan, T. M. The use of intravenous ribavirin to treat influenza virus-associated acute myocarditis. J. Infect Dis., 1989, 159, 829-836. Sanz, M.J.; Ferrandiz, M.J.; Cejudo, M.; Terencia, M.C.; Gil, B.; Bustos, G.; Ubeda, A.; Gunasegaran, R.; Alcaraz, M.M. Influence of a series of natural flavonoids on free radical generating systems, and oxidative stress. J. Xenobiotica, 1994, 24, 689-699. Schinazi, R.F.; Canno, D.L.; Arnold, B.H.; Martino-Saltzman, D. Combination of isoprinosine and 3'-azido-3'-deoxythymidine in lymphocytes infected with human immunodeficiency virus type 1. Antimicrob. Agents Chemother., 1988, 32, 1784-1787. Schinazi, R.F.; Sommadossi, J.P.; Saalman, V.; Cannan, M.W.; Hart, G.; Smith, G.; Hahn, E. Activity of 3'-azido-3'deoxythimidine nucleotide dimmers in primary lymphocytes infected with human immunodeficiency virus type 1. Antimicrob. Agents Chemother., 1990, 34, 1061-1067. Sidwell, R.W.; Bailey, D.W.; Wong, M.H.; Huffman, J.H.: In vitro and in vivo sensitivity of a non-mouse-adapted influenza (Bejing) virus infection to amantadine and ribavirin. Chemotherapy, 1995, 41, 455-461. Sidwell, R.; Huffman, R.; Gilbert, B.; Moscon, G.; Pedersen, R.; Burger, R.,; Warren, R. Utilization of pulse oximetry for the study of the inhibitory effects of antiviral agents on influenza virus in mice. Antimicrob. Ag. Chemother., 1992, 36, 473-476. Silva, G.L.; Chai, H.; Gupta, M.P.; Farnsworth, N.R.; Cordell, G.A.; Pezzuto, J.M.; Beecher, C.W.W.; Kinghorn, A.D. Cytotoxic biflavanoids from Selaginella willdenowii. Phytochemistry, 1995, 40, 129-134. Spira, T.J.; Bozeman, L.H.; Holman, R.C.; Warfield, K.T.; Phillips, S.K.; Feoprino, P.M. Micromethod for assaying the reverse transcriptase of LAV-HTIV-III/lymphadenopathy-associated virus. J. Clin. Microbiol., 1987, 25, 97-99. Tan, G.T.; Pezzuto, J.M.; Kinghorn, A.D. Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. J. Nat. Prod., 1991, 54, 143-154. Tisdale, M.; Bauer, D. J. The relative potencies of anti-influenza compounds. Ann. N. Y. Acad. Sci. 1977, 284, 254-263. Tsunoda, A.; Maasab, H. H.; Cochran, K. W.; Eveland, W. C. Antiviral activity of .sub..alpha. -methyl-1-adamantane methylamine hydrochloride. In Antimicrob. Agents Chemother. 1966, 553. van Leeuwen R.; Katlama, C.; Kitchen, V.; Boucher, C. A. B.; Tubiana, R.; McBride, M.; Ingrand, D.; Weber, J.; Hill, A.; McDade, H.; Damer S. A. Evaluation of safety and efficacy of 3TC (Lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: A phase I/II study. J. Inf. Dis. 1995, 171, 1166-1171. Yokoshuka, O.; Omata, O. M.; Imazeki, F.; Okauda, K.; Summers, J. Changes of hepatitis B virus DNA in liver and serum caused by recombinant leukocyte interferon treatment: analysis of intrahepatic replicative hepatitis B virus DNA. Hepatology 1985, 5, 728-734. Chen, et al., "Rhusflavanone, a New Biflavanone from the Seeds of Wax-tree," J. of The Chemical Society, pp. 98-101 (1976). Ezio, "Topical administration of plant extracts having therapeutic activities for treatment of fat deposits," Chem. Abst., vol. 115, Abst. No. 189759m (1991). Fujita, et al., "Nucleic acid determination by phosphatase-labeled DNA probe using fluorescent coumarin compounds as the enzyme substrate," Chem. Abst., vol. 115, Abst. No. 251633w (1991). Kadono, et al., "Antiviral powder, antiviral extract, and pharmaceutical preparation containing said powder and/or said extract," Chem. Abst., vol. 123, Abst. No. 208781w (1995). Kozuka, et al., "Hinokiflavone and kayaflavone as antiviral agents," Chem. Abst., vol. 113, Abst. No. 46254r (1989). Lamer-Zarawska, et al., "Chemical and taxonomic studies on some species from the Juniperus L. Genus," Chem. Abst., vol. 100, Abst. No. 117812r (1983). MAPE Establishment Ger. Offen. DE 3,544,457, "Garcinikolin, a biflavanoid from Garcinia kola, for treatment of liver disease," Chem. Abst., vol. 107, Abst. No. 211872b (1987). Spedding, et al., "Inhibition of reverse transcriptases by flavonoids," Antiviral Research, vol. 12, pp. 99-110 (1989). Tokuda, et al., "Bilobetin as virus genome inactivating agent," Chem. Abst., vol. 112, Abst. No. 16256e (1989). Wleklik, et al., "Interferon-inducing activity of flavonoids," Chem. Abst., vol. 107, Abst. No. 1267026 (1987). Wleklik, et al., "Structural basis for antiviral activity of flavonoids--naturally occurring compounds," Chem. Abst., vol. 111, Abst. No. 173 u (1988). Bernstein, et al., "Chemotherapy of Experimental Tuberculosis," The American Review of Tuberculosis, vol. 65, No. 4, pp. 357-364 (1952) U.S. Fa-Ching Chen, et al., "Phenolic compounds from the heartwood of garcinia multifolora," Phytochemistry, vol. 14, pp. 300-303 (1975) England. Fa-Ching Chen, et al., "Synthesis of Hexa-O-Methyl-8,8"-Binaringenin," Heterocycles, vol. 3, No. 10, pp. 833-835 (1975). Fa-Ching Chen, et al., "Synthesis of 7-Halogenoflavone and Related Compounds," J. Chem. Soc., pp. 146-150 (1958). Fa-Ching Chen, et al., "Synthesis of Halogenoflavonoids VIII. Synthesis of 6-Halogenoflavones and Related Compounds," J. Formosan Sci., vol. 8, pp. 74-75 (1954). Fa-Ching Chen, et al., "Synthesis of 6-Halogenoflavonoids and Related Compounds," J. Chem. Soc., pp. 3414-3417 (1961). Fa-Ching Chen, et al., "Synthesis of Halogenoflavonoids VII. Synthesis of 2-, 3-, and 4- Fluoro-2'-Oxychalcone," J. Formosan Sci., vol. 8, pp. 71-73 (1954) Taiwan. Collins, et al., "Microplate Alamar Blue Assay versus BACTEC 460 System for High-Throughput Screening of Compounds agains Mycobacterium tuberculosis and Mycobacterium avium," Antimicrob. Agents and Chemother., vol. 41, No. 5, pp. 1004-1009 (1997) U.S. H. Herbert Fox, "The Chemical Approach to the Control of Tuberculosis," Science, vol. 116, pp. 129-134 (1952) U.S. Inderlied, et al., "Antimicrobial Agents and Susceptibility Tests: Mycobacteria," Manual of Clinical Microbiology, 6.sup.th Ed., pp. 1385-1404 (1995) U.S. Ariyan, et al., "Heterocyclic Compounds of Chalcone Type," J. Chem. Soc., pp. 2242-2244 (1961). Fa-Ching Chen, et al., "Succedaneaflavanone--A New 6,6'-Binaringenin from RHUS Succedanea*," Phytochemistry, vol. 14, pp. 1644-1647 (1975) England. Fa-Ching Chen, et al., "Rhusflavanone, a New Biflavanone from the Seeds of Wax-tree," J. Chem. Soc., pp. 98-101 (1976). Fa-Ching Chen, et al., "Synthesis of Biflavonyls," Proc. Chem. Soc., pp. 232-240 (1959). Inderlied, et al, "Antimycobacterial Agents: In Vitro Susceptibility Testing, Spectra of Activity, Mechanisms of Action and Ressistance, and Assays for Activity in Biologic Fluids," Antibiotics in Laboratory Medicine, 4.sup.th Ed., pp. 127-175 (1996) U.S. Kohler, et al., "Benzalacetophenone," Organic Synthesis, vol. 2, No. 1, pp. 1-2 (1922). Yuh-Meei Lin, et al., "Agathisflavone from the drupes of RHUS Succedanea," Phytochemistry, vol. 13, pp. 657-658 (1974) England. Yuh-Meei Lin, et al., "Robustaflavone from the seed-kernels of THUS Succedanea," Phytochemistry, vol. 13, pp. 1617-1619 (1974) England. D.A. Mitchison, "The Garrod Lecture: Understanding the chemotherapy of tuberculosis--current problems," J. of Antimicrobial Chemotherapy, vol. 29, pp. 477-493 (1992) Britain. Nivin, et al., "A Continuing Outbreak of Multidrug-Ressistant Tuberculosis, with Transmission in a Hospital Nursery," Clin. Infect. Dis., vol. 26, pp. 303-307 (1988) U.S. F.N. Ozdemir, et al., "Tuberculosis Remains an Important Factor in the Morbidity and Mortality of Hemodialysis Patients," Transplantation Proceedings, vol. 30, pp. 846-847 (1998) U.S. Pablos-Mendez, et al., "Global Surveillance for Antituberculosis-drug Resistance," The New England Journal of Medicine, vol. 338, No. 23, pp. 1641-1649 (1998) U.S. Pansy, et al., "In Vitro Studies on Isonicotinic Acid Hydrazine," AM. Rev. Tuberc., vol. 65, pp. 761-764 (1952). A. Peterson, "FDA Approves the First New Treatment for Tuberculosis in More Than Decade," Wall Street Journal, pp. B5 (1998) U.S. Raviglione, et al., "Global Epidemiology of Tuberculosis," JAMA, vol. 273, No. 3, pp. 220-222 (1995) U.S. Robitzek, et al., "Hydrazine Derivatives of Isonicotinic Acid (Rimifon.sup.1, Marsilid.sup.2) in the Treatment of Active Progressive Caseous-Pneumonic Tuberculosis," Am. Rev. Tuberc., vol. 65, pp. 402-428 (1952). Siddiqi, "Radiometric (BACTEC) Tests for Slowly Growing Mycobacteria," American Society for Microbiology, pp. 5.14.2-5.14.25 (1992). Ben-Hur, et al., "Vitamin E and derivatives for prevention of damage in red cells sterilized by phthalocyanines and light," Chemical Abstracts, vol. 123, pp. 680 (208776y). Beretz, et al., "Inhibition of 3', 5+-AMP phosphodiesterase by biflavonoids and xanthones," 7-Enzymes, vol. 91, No. 1991, pp. 153422 (153416u). Hayashi, et al., "Mechanism of action of the antiherpesvirus biflavone ginkgetin," 1-Pharmatology, vol. 117, pp. 225798, 1991 (225973v). Ishitsuka, et al., "Antipicornavirus Flavone Ro 09-0179," Antimicrobioal Agents and Chemotherapy, vol. 22, No. 4, pp. 611-616, 1982. Kurokawa, et al., "Efficacy of traditional herbal medicines in combination with acyclovir against herpes simplex virus type 1 infection in vitro and in vivo," Chemical Abstracts, vol. 123, pp. 34, 1995 (334v). Kurokawa, et al., "Effects of traditional herbal medicines against herpes simplex virus (HSV) type 2 and acyclovir--resistant HSV type 1 in vitro and in vivo," Chemical Abstrcts, vol. 124, No. 21, 1996, (124:278137k). Lin, et al., "Medicinal Plants Used for the Treatment of Hepatitis in Taiwan," American J. of Chinese Medicine, vol. 18, Nos. 1-2, pp. 35-43, 1990. Lin, et al., "Antitumor agents. CII. Hinokiflavone, a cytotoxic principle from Rhus succedanea and the cytotoxicity of the related biflavonoids," 1-Pharmacology, vol. 111, pp. 70319, 1989 (70319v). Mucsi, et al., "Combined Effects of Flavonoids and Acyclovir Against Herpesviruses in Cell Cultures," Acta Microbiologica Hungarica, vol. 39, No. 2, pp. 137-147, 1992. Mucsi, et al., "Inhibition of virus multiplication and alteration of cyclic AMP level and cell cultures by flavonoids," Experientia, vol. 41, pp. 930-931, 1985. Reischle, et al., "Homeopathic remedies for treatment of damage to the immune system," 63-Phamaceuticals, vol. 122, pp. 64320, 1995 (64310w). Wleklilk et al., "Interferon--Inducing Activity of Flavonoids," ACTA Microbiologica Polonica, vol. 36, No. 1/2, 1987. Yukawa, et al., "Prophylactic treatment of cytomegalovirus infection with traditional herbs," Chemical Abstracts 1-Pharmacology, vol. 125, pp. 265067, 1996 (265061b). |
| PATENT PARENT CASE TEXT | This data is not available for free |
| PATENT CLAIMS |
What I claim: 1. A method for preventing or treating a mycobacterium infection in a mammal comprising administering to a mammal in need of anti-mycobacterium prevention or treatment an effective anti-mycobacterium amount of at least one compound of formula ii: ##STR17## wherein R.sub.1 =4-fluorophenyl-, 3-hydroxyphenyl-, pyridin-3-yl-, furan-2-yl-, phenanthren-2-yl-, 3-fluorenyl-, pyridin-2-yl-, naphthalen-1-yl-, pyridin-2-yl-, 4-bromo-2-hydroxyphenyl-, pyridin-4-yl-, 2-hydroxy-4-methoxyphenyl-, 4-aminophenyl-, pyridin-4-yl-, 2-hydroxy-5-methoxyphenyl-, 4-methoxyphenyl-, 4-methoxyphenyl-, 2-hydroxy-5-chlorophenyl-, 4-aminophenyl-, 3-hydroxynaphthalen-2-yl-, furan-2-yl- or pyridin-2-yl-; and R.sub.2 =pyridin-3-yl-, phenanthren-9-yl-, phenanthren-9-yl-, phenyl-, 2-aminopyridino-3-yl, 2-aminopyridino-3-yl-, pyridin-2-yl-, phenyl-, 4-dimethylaminophenyl-, furan-2-yl-, indol-2-yl-, furan-2-yl-, 2-aminopyridin-3-yl-, 4-dimethylaminophenyl-, furan-2-yl-, pyridin-4-yl-, pyridin-3-yl-, 2-amino-pyridin-3-yl-, 2-aminopyridin-3-yl-, 2-aminopyridin-3-yl-, pyridin-4-yl- or 4-methoxyphenyl-; or a pharmaceutically acceptable derivative or salt thereof and a pharmaceutically acceptable carrier therefor. 2. The method of claim 1 wherein R.sub.1 =4-fluorophenyl- and R.sub.2 =pyridin-3-yl-. 3. The method of claim 1 wherein R.sub.1 =3-hydroxyphenyl- and R.sub.2 =phenanthren-9-yl-. 4. The method of claim 1 wherein R.sub.1 =pyridin-3-yl- and R.sub.2 =phenanthren-9-yl-. 5. The method of claim 1 wherein R.sub.1 =furan-2-yl- and R.sub.2 =phenyl-. 6. The method of claim 1 wherein R.sub.1 =phenanthren-2-yl- and R.sub.2 =2-aminopyridino-3-yl-. 7. The method of claim 1 wherein R.sub.1 =3-fluorenyl- and R.sub.2 =2-aminopyridino-3-yl-. 8. The method of claim 1 wherein R.sub.1 =pyridin-2-yl- and R.sub.2 =pyridin-2-yl-. 9. The method of claim 1 wherein R.sub.1 =naphthalen-1-yl- and R.sub.2 =phenyl-. 10. The method of claim 1 wherein R.sub.1 =pyridin-2-yl- and R.sub.2 =4-dimethylaminophenyl-. 11. The method of claim 1 wherein R.sub.1 =4-bromo-2-hydroxyphenyl- and R.sub.2 =furan-2-yl-. 12. The method of claim 1 wherein R.sub.1 =pyridin-4-yl- and R.sub.2 =indol-2-yl-. 13. The method of claim 1 wherein R.sub.1 =2-hydroxy-4-methoxyphenyl-and R.sub.2 =furan-2-yl-. 14. The method of claim 1 wherein R.sub.1 =4-aminophenyl- and R.sub.2 =2-aminopyridin-3-yl-. 15. The method of claim 1 wherein R.sub.1 =pyridin-4-yl- and R.sub.2 =4-dimethylaminophenyl |
| PATENT DESCRIPTION |
FIELD OF THE INVENTION The present invention relates to methods and compositions for preventing or treating mycobacterium infections, particularly tuberculosis infections. BACKGROUND OF THE INVENTION Infectious diseases remain the largest cause of death in the world today, greater than cardiovascular disease or cancer..sup.1 Among infectious diseases, tuberculosis (TB) is the leading cause of death..sup.2 Tuberculosis, caused by the infection of Mycobacterium tuberculosis (Mtb), kills three million people worldwide and eight million people develop the disease each year according to current estimates by the World Health Organization (WHO). More people die from TB than from malaria, diarrhea, AIDS and tropical diseases combined. Tuberculosis mainly affects the lungs but can also involve other organs. TB strikes people of all ages, but is more common among the elderly. The disease can also afflict animals, especially livestock such as cattle, hogs and poultry. This disease once ranked among the most common causes of death in the world. Today, improved methods of prevention, detection, diagnosis and treatment have greatly reduced both the number of people who contract the disease and the number of people who die from it. However, in the last decade, the outbreaks of multidrug-resistant tuberculosis (MDRTB) and TB amplified by the global HIV pandemic make TB an urgent global issue. One third of the world's population is infected with Mtb,.sup.3 a facultative intracellular bacillus. After infection with Mtb, the lifetime risk of developing TB is approximately 10%, while 90% of infected persons have latent infection with viable bacilli. This 10% rate of TB accounts for the 8 million persons reported annually with active TB, and the resultant 3 million deaths. Moreover, TB is a serious problem faced by hemodialysis patients,.sup.4 and is the number one killer of women of childbearing age around the world, with 1.2 million women dying of the disease in 1997, according to reports by the WHO..sup.5 TB infection is a serious problem for acquired immunodeficiency syndrome (AIDS) patients. HIV-infected individuals are particularly susceptible to infection with Mtb and the development of TB. Compared to an individual who is not infected with HIV, an individual infected with HIV has a 10 times greater risk of developing TB. In an individual infected with HIV, the presence of other infections, including TB, may allow HIV to multiply more quickly. This may result in more rapid progression of HIV infection and AIDS..sup.6 As HIV infection progresses, CD4+ lymphocytes decline in number and function. The immune system is less able to prevent the growth and local spread of Mtb. Even in HIV-infected patients, pulmonary TB (PTB) is still the most common form of TB. The presentation of the disease depends on the degree of immunosuppression. As in adults, the natural history of TB in a child infected with HIV depends on the stage of HIV disease. Early in HIV infection, when immunity is strong, the signs of TB are similar to those in a child without HIV infection. As HIV infection progresses and immunity declines, dissemination of TB becomes more common and tuberculous meningitis, miliary tuberculosis, and widespread tuberculous lymphadenopathy occur more frequently. HIV-positive patients and staff in health units face daily exposure to TB. The risk of exposure is greatest in adult medical wards and TB wards where there are many PTB cases. From 1990-1992, the Centers for Disease Control (CDC) investigated outbreaks of MDRTB in several hospitals and a state correctional system. Almost 300 cases of MDRTB were identified in these outbreaks; most patients were HIV-seropositive. The mortality rate was 80%-90% and the median interval from diagnosis of tuberculosis to death ranged from 4-16 weeks..sup.7 In 1995, about one third of the 17 million HIV-infected people worldwide were also co-infected with Mtb..sup.6 Current treatment of TB requires taking at least two antibiotics, usually isoniazid and rifampicin, supplemented with pyrazinamide and ethambutol added when isoniazid resistance is suspected. Isoniazid (isonicotinic acid hydrazide) (INH) was first reported to be effective against Mtb and M. bovis in 1952..sup.8-10 Isoniazid, now still a front-line therapy against TB, has been shown to be an effective prophylactic antitubercular.sup.11, and modern short-course chemotherapy is initiated with three drugs: isoniazid, rifampin and pyrazinamide (PZA), often with the inclusion of a fourth drug, usually ethambutol. Recently, rifapentine, a derivative of rifamycin, was approved by the FDA for the treatment of tuberculosis..sup.12 The American Thoracic Society and the CDC in the United States now recommend a treatment regimen of isoniazid, rifampin and pyrazinamide for 2 months, followed by isoniazid and rifampin for an additional 4 months, as the standard 6-month regimen. Isoniazid, cheap and safe, has a wide therapeutic margin and high early bactericidal activity so that it kills rapidly growing bacilli in lesions, but is inefficient in ultimately sterilizing these lesions. Rifampin and PZA are crucial in achieving sterilization by killing persisting semi-dormant bacilli, and are thus responsible for shortening the duration of treatment from the earlier norm of 12-18 months to the current standard of 6 months..sup.13 However, many people fail to complete the lengthy therapy, treatment failures are high and MDR is increasing. A four-year study, led by the WHO, shows that of people who had been treated for TB for less than a month, 36 percent harbored microbes that resisted at least one of the four main anti-tuberculosis drugs. Moreover, 10% of infected people who had never been treated for the disease carried a strain of Mtb that resisted at least one drug..sup.14 Drug resistance resulting from inadequate treatment, such as irregular drug supply, inappropriate regimens or poor compliance is a potential threat to TB control programs throughout the world. Patients infected with strains resistant to multiple drugs are less likely to be cured, particularly if they are infected with HIV or malnourished, and their treatment is more toxic and more expensive than the treatment of patients with susceptible organisms. The resurgence of TB, the development of MDR to Mtb and the discovery that the progression of TB is accelerated in HIV-positive patients have intensified the need to develop more efficient drugs to combat this disease. BRIEF SUMMARY OF THE INVENTION The present invention relates to compounds, compositions and methods for treating and/or preventing mycobacterium infections, especially tuberculosis infections, in patients. The method is useful for treating or preventing mycobacterium infections in immunocomprised patients, particularly HIV infected patients. The present invention relates to compounds, compositions and methods for the prevention or treatment of mycobacterium infections. The compounds are naturally occurring and synthetic biflavonoids, flavonoids, chalcones and chalcone like compounds. The compounds were screened for anti-mycobacterium activity and several were found to cause inhibition of a mycobacterium infection. Of these, eight were identified as particularly potent, exhibiting greater than 90% inhibition of the growth of Mtb at a concentration of 12.5 .mu.g/mL. The actual minimum inhibitory concentrations (MIC), defined as the lowest concentration inhibiting 99% of the inoculum, for the preferred compounds ranged from 6.8 to 48.3 .mu.M. Accordingly, one object of the invention is a method for preventing or treating a mycobacterium infection in a mammal comprising administering to a mammal in need of anti-mycobacterium prevention or treatment an effective anti-mycobacterium amount of at least one compound of formula i. ##STR2## wherein R.sub.1 -R.sub.9 are independently comprised of H; OCH.sub.3 ; EtO; OH; O-alkenyl; phenyl; NH.sub.2 ; COOH; F; Cl; Br; I; CONH.sub.2 ; NO.sub.2 ; NR.sub.10 R.sub.11 OCONR.sub.10 R.sub.11 wherein R.sub.10 and R.sub.11 independently comprise H alkyl (e.g., C.sub.1-6 linear or branched alkyl) or aryl (e.g., unsubstituted phenyl or phenyl substituted with one or more of the following: C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy-C1-4 alkyl, hydroxyl, amino, C.sub.1-6 alkylamino, di(C.sub.1-6 alkyl)amino, amino-C.sub.1-8 alkyl, C.sub.1-8 alkylamino-C.sub.1-8 alkyl, di(C.sub.1-6 alkyl)amino-C.sub.1-8 alkyl, nitro, azido or halogen); COR.sub.12 wherein R.sub.12 comprises H, OH, O-alkyl (e.g., C.sub.1-6 linear or branched alkyl), O-aryl (e.g., unsubstituted phenyl or phenyl substituted with one or more of the following: C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy-C1-4 alkyl, hydroxyl, amino, C.sub.1-6 alkylamino, di(C.sub.1-6 alkyl)amino, amino-C.sub.1-8 alkyl, C.sub.1-8 alkylamino-C.sub.1-8 alkyl, di(C.sub.1-6 alkyl)amino-C.sub.1-8 alkyl, nitro, azido or halogen) or amino; NHCOCH.sub.3 ; O.sub.2.sup.- ; OCOR.sub.13 wherein R.sub.13 comprises alkyl (e.g., C.sub.1-6 linear or branched alkyl) or aryl (e.g., unsubstituted phenyl or phenyl substituted with one or more of the following: C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy-C1-4 alkyl, hydroxyl, amino, C.sub.1-6 alkylamino, di(C.sub.1-6 alkyl)amino, amino-C.sub.1-8 alkyl, C.sub.1-8 alkylamino-C.sub.1-8 alkyl, di(C.sub.1-6 alkyl)amino-C.sub.1-8 alkyl, nitro, azido or halogen); OAc; benzoyl; CONH.sub.2 ; or NO.sub.2 ; or a pharmaceutically acceptable derivative or salt thereof. Compounds of the formula i as well as anti-mycobacterium compositions comprising compounds of the formula i are included within this aspect of the invention. Another object of the invention is a method for preventing or treating a mycobacterium infection in a mammal comprising administering to a mammal in need of anti-mycobacterium prevention or treatment an effective anti-mycobacterium amount of at least one compound of formula ii. ##STR3## wherein R.sub.1 comprises 4-fluorophenyl-, 3-hydroxyphenyl-, pyridin-3-yl-, furan-2yl-, phenanthren-2-yl-, 3-fluorenyl-, pyridin-2-yl-, naphthalen-1-yl-, pyridin-2-yl-, 4-bromo-2-hydroxyphenyl-, pyridin-4-yl-, 2-hydroxy-4-methoxyphenyl-, 4-aminophenyl-, pyridin-4-yl-, 2-hydroxy-5-methoxyphenyl-, 4-methoxyphenyl-, 4-methoxyphenyl-, 2-hydroxy-5-chlorophenyl-, 4-aminophenyl-, 3-hydroxynaphthalen-2-yl-, furan-2-yl- or pyridin-2-yl-; and R.sub.2 comprises pyridin-3-yl-, phenanthren-9-yl-, phenanthren-9-yl-, phenyl-, 2-aminopyridino-3-yl, 2-aminopyridino-3-yl-, pyridin-2-yl-, phenyl-, 4-dimethylaminophenyl-, furan-2-yl-, indol-2-yl-, furan-2-yl-, 2-aminopyridin-3-yl-, 4-dimethylaminophenyl-, furan-2-yl-, pyridin-4-yl-, pyridin-3-yl-, 2-aminopyridin-3-yl-, 2-aminopyridin-3-yl-, 2-aminopyridin-3-yl-, pyridin-4-yl- or 4-methoxyphenyl-; or a pharmaceutically acceptable derivative or salt thereof. Compounds of the formula ii as well as anti-mycobacterium compositions comprising compounds of the formula ii are included within this aspect of the invention. Another object of the invention is a method for preventing or treating a mycobacterium infection in a mammal comprising administering to a mammal in need of anti-mycobacterium prevention or treatment an effective anti-mycobacterium amount of at least one compound of formula iii. ##STR4## wherein R.sub.1 -R.sub.8 are independently comprised of H; OCH.sub.3 ; EtO; OH; O-alkenyl; sdphenyl; NH.sub.2 ; COOH; F; Cl; Br; I; CONH.sub.2 ; NO.sub.2 ; NR.sub.10 R.sub.11 OCONR.sub.10 OR.sub.11 wherein R.sub.10 and R.sub.11 independently comprise H alkyl (e.g., C.sub.1-6 linear or branched alkyl) or aryl (e.g., unsubstituted phenyl or phenyl substituted with one or more of the following: C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy-C1-4 alkyl, hydroxyl, amino, C.sub.1-6 alkylamino, di(C.sub.1-6 alkyl)amino, amino-C.sub.1-8 alkyl, C.sub.1-8 alkylamino-C.sub.1-8 alkyl, di(C.sub.1-6 alkyl)amino-C.sub.1-8 alkyl, nitro, azido or halogen); COR.sub.12 wherein R.sub.12 comprises H, OH, O-alkyl (e.g., C.sub.1-6 linear or branched alkyl), O-aryl (e.g., unsubstituted phenyl or phenyl substituted with one or more of the following: C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy-C1-4 alkyl, hydroxyl, amino, C.sub.1-6 alkylamino, di(C.sub.1-6 alkyl)amino, amino-C.sub.1-8 alkyl, C.sub.1-8 alkylamino-C.sub.1-8 alkyl, di(C.sub.1-6 alkyl)amino-C.sub.1-8 alkyl, nitro, azido or halogen) or amino; NHCOCH.sub.3 ; O.sub.2.sup.- ; OCOR.sub.13 wherein R.sub.13 comprises alkyl (e.g., C.sub.1-6 linear or branched alkyl) or aryl (e.g., unsubstituted phenyl or phenyl substituted with one or more of the following: C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy-C1-4 alkyl, hydroxyl, amino, C.sub.1-6 alkylamino, di(C.sub.1-6 alkyl)amino, amino-C.sub.1-8 alkyl, C.sub.1-8 alkylamino-C.sub.1-8 alkyl, di(C.sub.1-6 alkyl)amino-C.sub.1-8 alkyl, nitro, azido or halogen); OAc; benzoyl; CONH.sub.2 ; or NO.sub.2 ; or pharmaceutically acceptable derivative or salt thereof. Compounds of the formula iii as well as anti-mycobacterium compositions comprising compounds of the formula iii are included within this aspect of the invention. Another object of the invention is a method for preventing or treating a mycobacterium infection in a mammal comprising administering to a mammal in need of anti-mycobacterium prevention or treatment an effective anti-mycobacterium amount of at least one compound of formula iv. ##STR5## wherein R.sub.1 -R.sub.8 are independently comprised of H; OCH.sub.3 ; EtO; OH; O-alkenyl; phenyl; NH.sub.2 ; COOH; F; Cl; Br; I; CONH.sub.2 ; NO.sub.2 ; NR.sub.10 R.sub.11 OCONR.sub.10 R.sub.11 wherein R.sub.10 and R.sub.11 independently comprise H alkyl (e.g., C.sub.1-6 linear or branched alkyl) or aryl (e.g., unsubstituted phenyl or phenyl substituted with one or more of the following: C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy-C1-4 alkyl, hydroxyl, amino, C.sub.1-6 alkylamino, di(C.sub.1-6 alkyl)amino, amino-C.sub.1-8 alkyl, C.sub.1-8 alkylamino-C.sub.1-8 alkyl, di(C.sub.1-6 alkyl)amino-C.sub.1-8 alkyl, nitro, azido or halogen); COR.sub.12 wherein R.sub.12 comprises H, OH, O-alkyl (e.g., C.sub.1-6 linear or branched alkyl), O-aryl (e.g., unsubstituted phenyl or phenyl substituted with one or more of the following: C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy-C1-4 alkyl, hydroxyl, amino, C.sub.1-6 alkylamino, di(C.sub.1-6 alkyl)amino, amino-C.sub.1-8 alkyl, C.sub.1-8 alkylamino-C.sub.1-8 alkyl, di(C.sub.1-6 alkyl)amino-C.sub.1-8 alkyl, nitro, azido or halogen) or amino; NHCOCH.sub.3 ; O.sub.2.sup.- ; OCOR.sub.13 wherein R.sub.13 comprises alkyl (e.g., C.sub.1-6 linear or branched alkyl) or aryl (e.g., unsubstituted phenyl or phenyl substituted with one or more of the following: C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy-C1-4 alkyl, hydroxyl, amino, C.sub.1-6 alkylamino, di(C.sub.1-6 alkyl)amino, amino-C.sub.1-8 alkyl, C.sub.1-8 alkylamino-C.sub.1-8 alkyl, di(C.sub.1-6 alkyl)amino-C.sub.1-8 alkyl, nitro, azido or halogen); OAc; benzoyl; CONH.sub.2 ; or NO.sub.2 ; or pharmaceutically acceptable derivative or salt thereof. Compounds of the formula iv as well as anti-mycobacterium compositions comprising compounds of the formula iv are included within this aspect of the invention. Yet another object of the invention is a method for treating or preventing mycobacterium infection in a patient comprising biflavonoid compounds, particularly 6-6"-biapigenin hexamethylether, volkensiflavone hexamethylether, GB-1a hexamethylether, 3"'-Nitro-C3-O-C4"'-biflavone, 3'-8"-biflavone, 6-2"'-biflavone, 6-6"-binaringenin hexamethyl-ether or 6-2"'-biapigenin or derivative or salt thereof and pharmaceutically acceptable carriers therefor. Still yet another object of the invention is to provide anti-mycobacterium composition comprising biflavonoid compounds for treating or preventing a mycobacterium infection in a patient particularly 6-6"-biagpigenin hexamethylether, volkensiflavone hexamethylether, GB-1a hexamethylether, 3"'-Nitro-C3-O-C4"'-biflavone, 3'-8"-biflavone, 6-2"'-biflavone, 6-6"-binaringenin hexamethylether or 6-2"'-biapigenin or derivative or salt thereof and pharmaceutically acceptable carriers therefor. These and other objects of the invention will be clear in light of the detailed description below. DETAILED DESCRIPTION OF THE INVENTION This invention relates to compounds, compositions and methods for treating or preventing mycobacterium infections in mammals. The compounds of the present invention are synthetic or naturally occurring chalcones, chalcone-like compounds, biflavonoids and flavonoids. The compounds were screened for anti-mycobacterium activity. Of the compounds showing anti-mycobacterium activity, eight were identified as particularly potent, exhibiting greater than 90% inhibition of the growth of Mtb at a concentration of 12.5 .mu.g/mL. The preferred compounds of this invention, which exhibited greater than 90% inhibition of the growth Mtb at a concentration of 12.5 .mu.g/mL, were chalcone-like compounds (heterocyclic ring substituted 2-propen-1-one) 1-(4-fluorophenyl)-3-(pyridin-3-yl)-2-propen-1-one (53) (98%), 1-(3-hydroxyphenyl)-3-phenanthren-9-yl-2-propen-one (54) (97%), 1-(5-pyridin-2-yl)-3-(phenanthen-9-yl)-2-propen-1-one (55) (96) and 1-(furan-2-yl)-3-phenyl-2-propen- 1-one (56) (96%); chalcones 1-(2-hydroxyphenyl)-3-(3-chlorophenyl)-2-propen-1-one (24) (90%) and 1-(2-hydroxyphenyl)-3-(3-iodophenyl)-2-propen-1-one (40) (92%); and biflavonoids 6-6"-biapigenin hexamethylether (151) (96%), and volkensiflavone hexamethylether (3-8"-naringenylapigenin hexamethylether) (152) (95%). The actual minimum inhibitory concentrations (MIC), defined as the lowest concentration inhibiting 99% of the inoculum, for 53, 54, 55, 56, 24, 40, and 151 were 6.8, 19.2, 20.2, 31.5, 48.3, >35.7 and >20.1 .mu.M, respectively. See Tables 1-5. The compounds and compositions of the present invention can be used to treat or prevent mycobacterium infections. Representative mycobacterial organisms include Mycobacterium aviurn complex (MAC), Mycobacterium kansaii, Mycobacterium marinum, Mycobacterium phlei, Mycobacterium ulcerans, Mycobacterium xenopi, Mycobacterium gordonae, Mycobacterium terrae complex, Mycobacterium haemophilum, Mycobacterium fortuitum, Mycobacterium tuberculosis, Mycobacterium laprae, Mycobacterium scrofulaceum and Mycobacterium smegmatis. In practicing this invention, the compounds and compositions are particularly useful in treating Mycobacterium tuberculosis infections. The compounds of the invention may be formulated as a solution of lyophilized powders for parenteral administration. Powders may be reconstituted by addition of a suitable diluent or other pharmaceutically acceptable carrier prior to use. The liquid formulation is generally a buffered, isotonic, aqeuous solution. Examples of suitable diluents are normal isotonic saline solution, standard 5% dextrose in water or in buffered sodium or ammonium acetate solution. Such formulation is especially suitable for parenteral administration, but may also be used for oral administration. It may be desirable to add excipients such as polyvinylpyrrolidone, gelatin, hydroxy cellulose, acacia, polyethylene glycol, mannitol, sodium choride or sodium citrate. Alternatively, the compounds of the present invention may be encapsulated, tableted or prepared in an emulsion (oil-in-water or water-in-oil) syrup for oral administration. Pharmaceutically acceptable solids or liquid carriers, which are generally known in the pharmaceutical formulary arts, may be added to enhance or stabilize the composition, or to facilitate preparation of the composition. Solid carriers include starch (corn or potato), lactose, calcium sulfate dihydrate, terra alba, croscarmellose sodium, magnesium stearate or stearic acid, talc, pectin, acacia, agar, gelatin, maltodextrins and microcrystalline cellulose, or colloidal silicon dioxide. Liquid carriers include syrup, peanut oil, olive oil, corn oil, sesame oil, saline and water. The carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax. The amount of solid carrier varies but, preferably, will be between about 10 mg to about 1 g per dosage unit. The dosage ranges for administration of the compounds of the invention are those necessary to produce the desired affect whereby symptoms of infection are ameliorated. For example, as used herein, an anti-mycobacterium effective amount for treating or preventing a mycobacterium infection refers to the amount administered so as to maintain an amount which suppresses or inhibits mycobacterium infection as evidenced by standard assay. The dosage will also be determined by the existence of any adverse side effects that may accompany the compounds. It is always desirable, whenever possible, to keep adverse side effects to a minimum. One skilled in the art can easily determine the appropriate dosage, schedule, and method of administration for the exact formulation of the composition being used in order to achieve the desired effective concentration in the individual patient. However, the dosage can vary from between about 0.001 mg/kg/day to about 50 mg/kg/day, but preferably between about 0.01 to about 1.0 mg/kg/day. The following examples are illustrative of the invention but does not serve to limit its scope. Experimental General Experimental Procedures Melting points were determined in open glass capillary tubes and are uncorrected. .sup.1 H-NMR and .sup.13 C-NMR spectra were recorded on a Varian XL300 NMR spectrometer in CDCl.sub.3, DMSO-d.sub.6 or acetone-d.sub.6 as specified using TMS as an internal standard. Chemical shifts are expressed in parts per million (.delta., ppm). IR spectra were recorded using a Midac FT-IR spectrometer, with samples being prepared as KBr pellets, or using a Perkin-Elmer spectrum 1000 FT-IR. Mass spectral data were recorded using a Finnegan MAT 90 mass spectrometer. Analytical thin-layer chromatography (TLC) was carried out on precoated plates (silica gel F.sub.254 from EM Science). Column chromatography was performed with silica gel 60 (70-230 mesh from EM Science). The structures of compounds were confirmed by their TLC profiles as well as their IR, NMR and MS spectra |
| PATENT EXAMPLES | available on request |
| PATENT PHOTOCOPY | available on request |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |